Strong Financial Position
LENZ Therapeutics ended Q1 2025 with approximately $194.1 million in cash, cash equivalents, and marketable securities. They received net proceeds of $16.3 million from a block trade, further strengthening their financial position.
High Engagement in Pre-Launch Campaigns
The unbranded EYEAMSELECTIVE campaign generated strong engagement with over 2 million impressions and reached over 12,000 eye care professionals (ECPs).
Positive Feedback from Commercial Day
The Commercial Day at the NASDAQ market site received extremely positive feedback, with many investors and analysts attending. The event demonstrated the strength of LENZ’s commercial strategy.
Sales Force and Commercial Readiness
LENZ has hired over 40% of its sales force, with 97% having prior eye care or pharma experience. The goal is to have the full field team in place by July 1st.
Strong Clinical Data
Phase III CLARITY study showed 90% of participants noticed an improvement in near vision, and 75% indicated they would continue using LNZ100.